Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Neratinib Chapter
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe | Nasdaq
Jon Mead - Vice President of FP&A - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
Puma Biotechnology, Inc.
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y
ADAPTING
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top | Nasdaq
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
PUMA_BIOTECHNOLOGY
